$PRTA
PROTHENA CORP PUBLIC LTD CO

2022 Q4 Form 10-Q Financial Statement

#000155905322000045 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $49.92M $1.517M
YoY Change 4159.64% -98.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.12M $11.99M
YoY Change 7.52% 0.28%
% of Gross Profit
Research & Development $36.87M $39.86M
YoY Change 67.15% 121.54%
% of Gross Profit
Depreciation & Amortization $196.0K $200.0K
YoY Change -18.33% -33.33%
% of Gross Profit
Operating Expenses $50.00M $51.85M
YoY Change 45.91% 73.14%
Operating Profit -$50.33M
YoY Change -146.08%
Interest Expense $3.744M $1.913M
YoY Change 31100.0% 17290.91%
% of Operating Profit
Other Income/Expense, Net -$327.0K $1.915M
YoY Change 1943.75% -6277.42%
Pretax Income $3.345M -$48.42M
YoY Change -110.11% -144.34%
Income Tax -$3.004M -$2.700M
% Of Pretax Income -89.81%
Net Earnings $6.349M -$45.76M
YoY Change -119.14% -141.89%
Net Earnings / Revenue 12.72% -3016.74%
Basic Earnings Per Share -$0.97
Diluted Earnings Per Share $0.13 -$0.97
COMMON SHARES
Basic Shares Outstanding 48.38M shares 46.92M shares
Diluted Shares Outstanding 46.99M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $710.4M $495.6M
YoY Change 22.68% -17.41%
Cash & Equivalents $710.4M $495.6M
Short-Term Investments
Other Short-Term Assets $8.692M $28.93M
YoY Change 52.09% 293.5%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $719.1M $524.6M
YoY Change 22.96% -13.66%
LONG-TERM ASSETS
Property, Plant & Equipment $1.731M $1.997M
YoY Change -13.97% 2.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.51M $3.747M
YoY Change 425.91% 107.25%
Total Long-Term Assets $38.94M $29.88M
YoY Change 58.56% 18.69%
TOTAL ASSETS
Total Short-Term Assets $719.1M $524.6M
Total Long-Term Assets $38.94M $29.88M
Total Assets $758.0M $554.4M
YoY Change 24.4% -12.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.270M $9.788M
YoY Change 151.15% 181.02%
Accrued Expenses $28.33M $29.77M
YoY Change 35.31% 71.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $50.15M $50.60M
YoY Change 49.91% 73.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $553.0K $553.0K
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $85.85M $99.19M
YoY Change -21.87% -12.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $50.15M $50.60M
Total Long-Term Liabilities $85.85M $99.19M
Total Liabilities $136.0M $149.8M
YoY Change -5.11% 5.31%
SHAREHOLDERS EQUITY
Retained Earnings -$833.0M -$839.4M
YoY Change 16.33% 22.92%
Common Stock $521.0K $479.0K
YoY Change 11.8% 3.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $622.0M $404.6M
YoY Change
Total Liabilities & Shareholders Equity $758.0M $554.4M
YoY Change 24.4% -12.37%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $6.349M -$45.76M
YoY Change -119.14% -141.89%
Depreciation, Depletion And Amortization $196.0K $200.0K
YoY Change -18.33% -33.33%
Cash From Operating Activities -$4.976M -$31.17M
YoY Change -77.84% -127.8%
INVESTING ACTIVITIES
Capital Expenditures $151.0K -$130.0K
YoY Change -147.34% -37.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$151.0K -$130.0K
YoY Change -52.66% -37.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 220.8M 18.13M
YoY Change 12351.49% -79.16%
NET CHANGE
Cash From Operating Activities -4.976M -31.17M
Cash From Investing Activities -151.0K -130.0K
Cash From Financing Activities 220.8M 18.13M
Net Change In Cash 215.6M -13.17M
YoY Change -1126.65% -106.62%
FREE CASH FLOW
Cash From Operating Activities -$4.976M -$31.17M
Capital Expenditures $151.0K -$130.0K
Free Cash Flow -$5.127M -$31.04M
YoY Change -76.84% -127.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 prta Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord
OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord
0.50
CY2022Q3 us-gaap Contractual Obligation
ContractualObligation
500000 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001559053
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 prta Lease Agreement Term Of Contract
LeaseAgreementTermOfContract
P7Y9M30D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35676
dei Entity Registrant Name
EntityRegistrantName
PROTHENA CORPORATION PUBLIC LIMITED COMPANY
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1111119
dei Entity Address Address Line1
EntityAddressAddressLine1
77 Sir John Rogerson’s Quay, Block C
dei Entity Address Address Line2
EntityAddressAddressLine2
Grand Canal Docklands
dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 2,
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D02 VK60,
dei Entity Address Country
EntityAddressCountry
IE
dei Country Region
CountryRegion
353
dei City Area Code
CityAreaCode
1
dei Local Phone Number
LocalPhoneNumber
236-2500
dei Security12b Title
Security12bTitle
Ordinary Shares, par value $0.01 per share
dei Trading Symbol
TradingSymbol
PRTA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48376566 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
495628000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
579094000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
28934000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5715000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
524562000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
584809000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2012000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7808000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12123000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
14974000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
7071000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1352000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1352000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3747000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1999000 usd
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
29878000 usd
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
24557000 usd
CY2022Q3 us-gaap Assets
Assets
554440000 usd
CY2021Q4 us-gaap Assets
Assets
609366000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9788000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3691000 usd
CY2022Q3 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
11593000 usd
CY2021Q4 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6351000 usd
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9665000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7657000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6385000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5940000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13167000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9813000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
50598000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33452000 usd
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
96992000 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
102933000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1649000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6386000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
553000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
553000 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
99194000 usd
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
109872000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
149792000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
143324000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2022Q3 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2022Q3 prta Deferred Shares Value
DeferredSharesValue
0 usd
CY2021Q4 prta Deferred Shares Value
DeferredSharesValue
0 usd
CY2021Q4 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2022Q3 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1181630000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-839352000 usd
CY2022Q3 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2021Q4 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2022Q3 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2021Q4 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
479000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
466000 usd
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47885755 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47885755 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46660294 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46660294 shares
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1243521000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-716054000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
404648000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
466042000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
554440000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
609366000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1517000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
139174000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3982000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
199405000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39860000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17992000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98691000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60226000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11989000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11955000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36776000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34112000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
51849000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
29947000 usd
us-gaap Operating Expenses
OperatingExpenses
135467000 usd
us-gaap Operating Expenses
OperatingExpenses
94338000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-50332000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
109227000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-131485000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
105067000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1913000 usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
11000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2605000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
30000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-80000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1915000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2535000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-50000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48417000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
109196000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-128950000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
105017000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2653000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-51000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5652000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4863000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45764000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
109247000 usd
us-gaap Net Income Loss
NetIncomeLoss
-123298000 usd
us-gaap Net Income Loss
NetIncomeLoss
100154000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.12
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46986000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45626000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46833000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43422000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46986000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51205000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2219686 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46833000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47196000 shares
us-gaap Net Income Loss
NetIncomeLoss
-123298000 usd
us-gaap Net Income Loss
NetIncomeLoss
100154000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
548000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
875000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23889000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
17771000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-7903000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
5141000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4466000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4244000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
64000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4997000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6291000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11826000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4202000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4443000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4085000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3933000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1520000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103845000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
115063000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
313000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
256000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-313000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-256000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6210000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13694000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20692000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
188559000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-83466000 usd
CY2018Q3 prta Subleaserentals Annual Base Rent Initial Amount
SubleaserentalsAnnualBaseRentInitialAmount
2700000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
303366000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
580446000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298084000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
496980000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
601450000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2374000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
568000 usd
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
220000 usd
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
11000 usd
prta Non Cash Financing Receivable From Option Exercises
NonCashFinancingReceivableFromOptionExercises
3267000 usd
prta Non Cash Financing Receivable From Option Exercises
NonCashFinancingReceivableFromOptionExercises
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
151000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
prta Proceeds From At The Market Offering In Transit
ProceedsFromAtTheMarketOfferingInTransit
13744000 usd
prta Proceeds From At The Market Offering In Transit
ProceedsFromAtTheMarketOfferingInTransit
0 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
495628000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
600098000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1352000 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1352000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
496980000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
601450000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
466042000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7660000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1475000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36290000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
438887000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8263000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
427000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-41244000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
407299000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7966000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7562000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45764000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
404648000 usd
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
184006000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6176000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3083000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-36735000 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
234584000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5540000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6479000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
27642000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
288207000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6055000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4132000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
109247000 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
490471000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-839400000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
495600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Concentration of Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> trade accounts receivables recorded in t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Condensed Consolidated Balance Sheet as of September 30, 2022. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business is primarily conducted in U.S. dollars except for its agreements with contract manufacturers for drug supplies which are denominated in Euros and other foreign currencies. The Company recorded a loss on foreign currency exchange rate differences of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$70,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$80,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the nine months ended September 30, 2022 and 2021, respectively. If the Company increases its business activities that require the use of foreign currencies, it may be exposed to losses if the Euro and other such currencies strengthen against the U.S. dollar.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, and December 31, 2021, approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $2.0 million, respectively, of the Company’s property and equipment, net were held in the U.S. and nominal amounts were in Ireland.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div>
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
70000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
80000 usd
CY2022Q3 prta Receivable From Stock Option Exercises In Transit
ReceivableFromStockOptionExercisesInTransit
3267000 usd
CY2021Q4 prta Receivable From Stock Option Exercises In Transit
ReceivableFromStockOptionExercisesInTransit
13000 usd
CY2022Q3 prta Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
6058000 usd
CY2021Q4 prta Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
3859000 usd
CY2022Q3 prta Prepaid General And Administrative Expense
PrepaidGeneralAndAdministrativeExpense
2395000 usd
CY2021Q4 prta Prepaid General And Administrative Expense
PrepaidGeneralAndAdministrativeExpense
1077000 usd
CY2022Q3 prta Receivable From At The Market Offering
ReceivableFromAtTheMarketOffering
13744000 usd
CY2021Q4 prta Receivable From At The Market Offering
ReceivableFromAtTheMarketOffering
0 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3470000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
766000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
28934000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5715000 usd
CY2022Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
9871000 usd
CY2021Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
9758000 usd
CY2022Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1660000 usd
CY2021Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1393000 usd
CY2022Q3 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
1466000 usd
CY2021Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
1322000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12997000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12473000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11000000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10461000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1997000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2012000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
200000 usd
us-gaap Depreciation
Depreciation
500000 usd
CY2021Q3 us-gaap Depreciation
Depreciation
300000 usd
us-gaap Depreciation
Depreciation
900000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11792000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8644000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
661000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
764000 usd
CY2022Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
714000 usd
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
405000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13167000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9813000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45764000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
109247000 usd
us-gaap Net Income Loss
NetIncomeLoss
-123298000 usd
us-gaap Net Income Loss
NetIncomeLoss
100154000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46986000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45626000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46833000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43422000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
0 shares
CY2018Q3 prta Operating Leases Sublease Rentals Percent Annual Rent Increase
OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease
0.035
CY2021Q3 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
5579000 shares
us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
0 shares
us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
3774000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46986000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51205000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46833000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47196000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.12
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
700000 usd
us-gaap Sublease Income
SubleaseIncome
2200000 usd
CY2018Q3 prta Operating Leases Sublease Rentals Termof Contract
OperatingLeasesSubleaseRentalsTermofContract
P5Y2M12D
CY2016Q1 prta Operating Lease Area
OperatingLeaseArea
128751 sqft
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M
CY2016Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-12-31
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1600000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
4800000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1600000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
4800000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1600000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
4700000 usd
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1500000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
4600000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0425
CY2018Q3 prta Operating Leases Sublease Rentals Areaof Sublease Rental
OperatingLeasesSubleaseRentalsAreaofSubleaseRental
46641 sqft
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
700000 usd
us-gaap Sublease Income
SubleaseIncome
2200000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1649000 usd
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
779000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6617000 usd
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
3019000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0 usd
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
0 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 usd
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
0 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8266000 usd
CY2022Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
3798000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
232000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8034000 usd
CY2022Q3 us-gaap Purchase Obligation
PurchaseObligation
12400000 usd
CY2022Q3 us-gaap Purchase Obligation
PurchaseObligation
12365000 usd
CY2022Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
12365000 usd
CY2022Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
0 usd
CY2022Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 usd
CY2022Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 usd
CY2022Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 usd
CY2022Q3 prta Purchase Obligation To Be Paid After Year Four
PurchaseObligationToBePaidAfterYearFour
0 usd
CY2022Q3 prta Purchaseand Contractual Obligation Total
PurchaseandContractualObligationTotal
12836000 usd
CY2022Q3 prta Purchaseand Contractual Obligation Remainderof Fiscal Year
PurchaseandContractualObligationRemainderofFiscalYear
12424000 usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
176000 shares
CY2022Q3 prta Purchase And Contractual Obligation Due In Year One
PurchaseAndContractualObligationDueInYearOne
74000 usd
CY2022Q3 prta Purchaseand Contractual Obligation Duein Second Year
PurchaseandContractualObligationDueinSecondYear
64000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022Q3 prta Purchaseand Contractual Obligation Duein Third Year
PurchaseandContractualObligationDueinThirdYear
64000 usd
CY2022Q3 prta Purchaseand Contractual Obligation Duein Fourth Year
PurchaseandContractualObligationDueinFourthYear
60000 usd
CY2022Q3 prta Purchase And Contractual Obligation Due After Fourth Year
PurchaseAndContractualObligationDueAfterFourthYear
150000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47885755 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47885755 shares
prta Numberof Votes
NumberofVotes
1 vote
CY2022Q3 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2022Q3 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2022Q3 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
193500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3323477 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1372587 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3170580 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10018665 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.32
CY2021Q1 prta Number Of Ordinary Shares Tendered For Exchange Under The Option Exchage
NumberOfOrdinarySharesTenderedForExchangeUnderTheOptionExchage
2100000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1400000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.85
CY2021Q1 prta Share Based Compensation Arrangement By Share Based Payment Award Options Minimum Exchange Threshold Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumExchangeThresholdExercisePrice
17.63
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
74100000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M19D
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
7966000 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
6055000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23889000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
17771000 usd
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.823
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.828
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.822
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.816
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.029
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
20.38
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
45.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.60
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8684322 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.20
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M23D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
269182000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2219686 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
31.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
711432 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
173911 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10018665 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M17D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
386761000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9603058 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
21.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y9M14D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
374078000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
5892682 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M10D
CY2022Q3 prta Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions
253936000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5700000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-51000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4900000 usd
prta Deferred Tax Assets Period Increase Decrease
DeferredTaxAssetsPeriodIncreaseDecrease
7900000 usd

Files In Submission

Name View Source Status
0001559053-22-000045-index-headers.html Edgar Link pending
0001559053-22-000045-index.html Edgar Link pending
0001559053-22-000045.txt Edgar Link pending
0001559053-22-000045-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
prta-20220930.htm Edgar Link pending
prta-20220930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
prta-20220930_def.xml Edgar Link unprocessable
prta-20220930_cal.xml Edgar Link unprocessable
prta-20220930_pre.xml Edgar Link unprocessable
prta2022q310-qxex311.htm Edgar Link pending
prta2022q310-qxex312.htm Edgar Link pending
prta2022q310-qxex321.htm Edgar Link pending
prta2022q3xex104selkoecons.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
prta-20220930_lab.xml Edgar Link unprocessable
prta-20220930_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending